Dr. Arvind Argikar: Guest Editor for May 2021

This month’s issue on metabolic health digest is unique as this edition provides an elaborate understanding of COVID-19 and discusses guidelines for better application of treatment strategies in order to improve patient outcomes.

I have been a clinician for the last 40 years and have applied the latest evidence in practice. The chances of updating and applying new treatment approaches have been widened with articles that discuss guidelines on Antithrombotic therapy for COVID-19 as a treatment strategy and some shedding light on extracorporeal membrane oxygenation (ECMO) as a new way of treating critically ill patients with COVID-19. Amidst many contrasting theories, a summarized article with evidence that support that covid-19 has an airborne mode of transmission is something one should definitely give a read.

I have personally got impressed to read an article that discusses the unique shift in the management of diabetes in a digital way, while there is a long way to go, we at least got such approaches in practice.
Metabolic health digest is filling the gap by providing a summarization for guidelines that discusses the management of Stage 1 Hypertension in Adults with a Low 10-Year Risk for Cardiovascular Disease, a subset of patients where a mention was not there in any guidelines. Benefits of medications such as novel SGLT2 inhibitor, polypill (40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril), and aspirin for cardiovascular events need to be taken into practice by the fraternity.